| Literature DB >> 23294984 |
Giovanni Motta1, Sergio Motta, Pasquale Cassano, Salvatore Conticello, Massimo Ferretti, Bruno Galletti, Aldo Garozzo, Gennaro Larotonda, Nicola Mansi, Emilio Mevio, Gaetano Motta, Giuseppe Quaremba, Agostino Serra, Vincenzo Tarantino, Paolo Tavormina, Claudio Vicini, Maurizio Giovanni Vigili, Domenico Testa.
Abstract
BACKGROUND: Several guidelines on adeno-tonsillar disease have been proposed in recent years and some discrepancies in relation both to clinical manifestations and indications for surgical treatment have emerged. The aim of the study was to verify what influence (adeno)-tonsillectomy guidelines have had on the clinical behaviour of ENT specialists in Italy. Our study is a retrospective and multi-centre case series with chart review.Entities:
Year: 2013 PMID: 23294984 PMCID: PMC3545732 DOI: 10.1186/1472-6815-13-1
Source DB: PubMed Journal: BMC Ear Nose Throat Disord ISSN: 1472-6815
The indications to pharyngeal surgical interventions provided in the questionnaire
| 1. < 5 FEART a year without NRO * | 1. < 5 FEART a year without NRO |
| 2. < 5 FEART a year with NRO * | 2. < 5 FEART a year with NRO |
| 3. ≥ 5 FEART a year without NRO ° | 3. ≥ 5 FEART a year without NRO |
| 4. ≥ 5 FEART a year with NRO ° | 4. ≥5 FEART a year with NRO |
| 5. GABHS infection ° | 5. NRO |
AT = Adeno-Tonsillectomy; T = Tonsillectomy; A= Adenoidectomy; FEART = Feverish Episodes due to Acute Recurrent Tonsillitis; NRO = Nasal Respiratory Obstruction. GABHS = Group A β Hemolytic Streptococcus.
* not in accordance with Italian GL; ° in accordance with Italian GL.
Figure 1Trends of operated cases. The dashed line indicates the introduction of PD in 2003 in Italy. AT = Adeno-Tonsillectomy; T = Tonsillectomy; A= Adenoidectomy.
Trend in absolute numbers and percentages of AT, T and A
| | ||||||
|---|---|---|---|---|---|---|
| | | | | | | |
| < 5 FEART without NRO | 56 (2.3%) | 47 (2.0%) | 43 (1.8%) | 44 (2.0%) | 190 (2.0%) | 0.539 |
| < 5 FEART with NRO | 855 (34.5%) | 955 (41.3%) | 914 (37.5%) | 809 (36.1%) | 3533 (37.3%) | 1 |
| ≥ 5 FEART without NRO | 344 (13.9%) | 309 (13.4%) | 268 (11.0%) | 235 (10.5%) | 1156 (12.2%) | 0.010 |
| ≥ 5 FEART with NRO | 990 (40.0%) | 779 (33.7%) | 984 (40.4%) | 920 (41.0%) | 3673 (38.8%) | 0.637 |
| GABHS infection | 233 (9.4%) | 223 (9.6%) | 227 (9.3%) | 234 (10.4%) | 917 (9.7%) | 0.553 |
| 2478 | 2313 | 2436 | 2242 | 0.307 | ||
| (100%) | (100%) | (100%) | (100%) | |||
| | | | | | | |
| < 5 FEART without NRO | 6 (4.3%) | 24 (10.9%) | 9 (4.8%) | 3 (1.8%) | 42 (5.9%) | 0.605 |
| < 5 FEART with NRO | 9 (6.5%) | 25 (11.3%) | 23 (12.4%) | 20 (11.8%) | 77 (10.8%) | 0.132 |
| ≥ 5 FEART without NRO | 72 (52.2%) | 106 (48.0%) | 74 (39.8%) | 71 (42.0%) | 323 (45.2%) | 0.109 |
| ≥ 5 FEART with NRO | 40 (29.0%) | 46 (20.8%) | 58 (31.2%) | 65 (38.5%) | 209 (29.3%) | 0.317 |
| GABHS infection | 11 (8.0%) | 20 (9.0%) | 22 (11.8%) | 10 (5.9%) | 63 (8.8%) | 0.845 |
| 138 | 221 | 186 | 169 | 0.784 | ||
| (100%) | (100%) | (100%) | (100%) | |||
| 2616 (100%) | 2534 | 2622 | 2411 | 0.309 | ||
| (100%) | (100%) | (100%) | (100%) | | ||
| | | | | | | |
| < 5 FEART without NRO | 285 (21.9%) | 237 (20.4%) | 293 (28.1%) | 265 (24.6%) | 1080 (23.5%) | 0.373 |
| < 5 FEART with NRO | 379 (29.1%) | 282 (24.3%) | 254 (24.3%) | 277 (25.7%) | 1192 (26.0%) | 0.508 |
| ≥ 5 FEART without NRO | 25 (1.9%) | 17 (1.5%) | 9 (0.9%) | 13 (1.2%) | 64 (1.4%) | 0.225 |
| ≥ 5 FEART with NRO | 241 (18.5%) | 259 (22.3%) | 236 (22.6%) | 211 (19.6%) | 947 (20.6%) | 0.592 |
| NRO | 373 (28.6%) | 367 (31.6%) | 252 (24.1%) | 312 (28.9%) | 1304 (28.4%) | 0.689 |
| 1303 | 1162 | 1044 | 1078 | 0.113 | ||
| (100%) | (100%) | (100%) | (100%) | |||
AT = Adeno-Tonsillectomy; T = Tonsillectomy; A= Adenoidectomy; FEART = Feverish Episodes due to Acute Recurrent Tonsillitis; NRO = Nasal Respiratory Obstruction. GABHS = Group A β Hemolytic Streptococcus.
Main indications for T and AT and number of recommendations related to to surgical management in GL on adeno-tonsillar disease
| ≥ 5 a year | C/A-C | Not mentioned | Not mentioned | 3 | |
| ≥ 3 a year | - | Hypertrophy causing upper airway obstruction | RAOM or EOM | 8 | |
| ≥ 5 a year | A/A-D | OSAS | Surgery is not recommended | 53 | |
| ≥ 5 a year | A/A-D | OSAS | Surgery is not recommended | 79 | |
| ≥ 7 in the last year | D/A-D | Not mentioned | Not mentioned | 4 | |
| | ≥ 5 in the last 2 years | | | | |
| | ≥ 3 in the last 3 years | | | | |
| ≥ 7 in the last year | B/A-D | Sleep Disordered Breathing (SDB), including snoring, mouth breathing, pauses in breathing, etc. (“ | Not mentioned | 10 | |
| | ≥ 5 in the last 2 years | | | | |
| ≥ 3 in the last 3 years |
GL = Guidelines; FEART = Feverish Episodes due to Acute Recurrent Tonsillitis; NRO = Nasal Respiratory Obstruction. SIGN = Scottish Intercollegiate Guidelines Network; AAOHNS = American Academy of Otolaryngology-Head and Neck Surgery; PNLG =Programma Nazionale Linee Guida; SNLG = Sistema Nazionale Linee Guida. Strength of the recommendation related to the number of FEART.